Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.26 USD

51.26
3,013,431

-1.59 (-3.01%)

Updated Nov 6, 2024 03:59 PM ET

Pre-Market: $51.43 +0.17 (0.33%) 9:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss

Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.

    Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

    Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.

      ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

      ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.

        Sanghamitra Saha headshot

        6 European Stocks to Shun on Tapered IMF Outlook

        IMF lowered its growth projection for in Germany, France and Italy. Time to avoid these sell-ranked stocks?

          Regulus Stock Plunges on Cash Concerns Despite Restructuring

          Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.

            Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion

            Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.

              Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

              Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.

                Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

                Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.

                  Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?

                  Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.

                    Indrajit Bandyopadhyay headshot

                    5 Biotech Stocks Under $10 Worthy of Investors' Attention

                    Small biotech stocks are good bets with lower market cap as well as share price.

                      Alexion-Complement Pharma Tie Up to Treat Neuro Disorders

                      Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.

                        Alnylam Reports Positive Data on Lumasiran in Renal Disease

                        Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

                          The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

                          The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

                            Indrajit Bandyopadhyay headshot

                            3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

                            Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.

                              Kinjel Shah headshot

                              5 Biotech Stocks to Boost Your Portfolio's Health This Year

                              Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.

                                The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery

                                The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery

                                  Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

                                  Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

                                    Mark Vickery headshot

                                    Top Research Reports for UnitedHealth, United Technologies & Eni

                                    Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), United Technologies (UTX) and Eni (E).

                                      Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

                                      Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

                                        Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

                                        Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

                                          BioMarin Begins Mid Stage Study on Gene Therapy Candidate

                                          BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.

                                            Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

                                            Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

                                              Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

                                              Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

                                                Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

                                                Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

                                                  Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

                                                  Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.